HIV. An individual received 12 treatments with the device, administered three times a week over a period of 30 days. Results from the study, carried out in Punjab, India, are expected to be released later this month although preliminary reports indicate that the treatment was well–tolerated.Aethlon Medical Inc., has recently announced that it has completed its first in–man trials of the Hemopurifier for the treatment of
The Hemopurifier is a therapeutic filtration device to reduce viral load in a patient’s blood, working as a boost to the immune system. Preclinical studies in human blood demonstrated that the device is capable of capturing HIV, hepatitis C virus and orthopox viruses. The Hemopurifier has also been tested in three individuals with hepatitis C, and results from this study were published recently in Blood Purification.
“Based on previous treatment outcomes in hepatitis C patients, we are cautiously optimistic that the data resulting from our first HIV study will also prove to be positive,” commented Jim Joyce, Chairman and CEO of Aethlon Medical.
Contributed By: M Neelam Kachhap
Source: Aethlon Medical Inc. http://www.aethlonmedical.com. Tullis RH, Duffin RP, Handley HH et al. Reduction of hepatitis C virus using lectin affinity plasmapheresis in dialysis patients. Blood Purif. 27(1), 64–69 (2009).
Tuesday, Feb 21st
Last update:05:44:44 AM IST